DE2362396A1 - CARBAMATES OF 4-HYDROXY-8-ALKOXY-2,9DIOXATRICYCLO SQUARE BRACKET TO 4,3,1,0 HIGH 3,7 SQUARE BRACKET TO DECANES - Google Patents
CARBAMATES OF 4-HYDROXY-8-ALKOXY-2,9DIOXATRICYCLO SQUARE BRACKET TO 4,3,1,0 HIGH 3,7 SQUARE BRACKET TO DECANESInfo
- Publication number
- DE2362396A1 DE2362396A1 DE2362396A DE2362396A DE2362396A1 DE 2362396 A1 DE2362396 A1 DE 2362396A1 DE 2362396 A DE2362396 A DE 2362396A DE 2362396 A DE2362396 A DE 2362396A DE 2362396 A1 DE2362396 A1 DE 2362396A1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- square bracket
- methoxy
- alkoxy
- dioxatricyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title abstract description 3
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 abstract description 17
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 2
- 231100001231 less toxic Toxicity 0.000 abstract description 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003874 central nervous system depressant Substances 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- HXBPYFMVGFDZFT-UHFFFAOYSA-N allyl isocyanate Chemical compound C=CCN=C=O HXBPYFMVGFDZFT-UHFFFAOYSA-N 0.000 description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- -1 chloroformic acid ester Chemical class 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- KBJXDTIYSSQJAI-UHFFFAOYSA-N propylcarbamic acid Chemical class CCCNC(O)=O KBJXDTIYSSQJAI-UHFFFAOYSA-N 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
23623362362336
Hannover, 12. Dezember 1972 Z3-PA.MH/KaHanover, December 12, 1972 Z3-PA.MH/Ka
■ Patentanmeldung Carbamate der 4-Hydroxy-8- alkoxy-2t9-dioxatricycle» ■ Patent application for carbamates of the 4-hydroxy-8-alkoxy-2 t 9-dioxatricycle »
Zusatz zu Patent (Patentanmeldung P 23 06 118.9)Addendum to patent (patent application P 23 06 118.9)
In der Patentanmeldung P 23 06 118.9 sind 4-Hydroxy-8-alkoxy-2,9-dioxatricyclof4,3,1,0^''Jdecane und deren Ester beschrieben mit folgender allgemeiner Formel:In the patent application P 23 06 118.9 are 4-hydroxy-8-alkoxy-2,9-dioxatricyclof4,3,1,0 ^ "Jdecane and their esters described with the following general formula:
in welcher R^ einen Alkylrest mit 1 bis 4 C-Atomen, R = OH, OCO-R, , OCONH-R5 bedeuten, wenn R-, Wasserstoff ist, und R, OCONH-R5 bedeutet, wenn Rp Wasserstoff ist, wobei R, für eine Alkylgruppe mit 1 bis 4 C-Atomen und R5 für Wasserstoff oder eine Alkylgruppe mit 1 bis 4 C-Atomen steht und die 10,11-Doppelbindung hydriert sein kann.in which R ^ is an alkyl radical with 1 to 4 carbon atoms, R = OH, OCO-R,, OCONH-R 5 when R- is hydrogen, and R, OCONH-R 5 is when Rp is hydrogen, where R 1 stands for an alkyl group with 1 to 4 carbon atoms and R 5 for hydrogen or an alkyl group with 1 to 4 carbon atoms and the 10,11 double bond can be hydrogenated.
Gegenstand der vorliegenden"Erfindung sind Carbamate der 4- Hydroxy-8-alkoxy-2,9-dioxatricyclor4,3,1 t0 Jdecane der allge meinen Formel IThe present invention relates to carbamates of 4-hydroxy-8-alkoxy-2,9-dioxatricyclor4.3.1 t 0 decanes of the general formula I.
5 09825/106 05 09825/106 0
= OCONHR5 bedeuin welcher R1 ein Alkylrest mit 1 bis 4 C-Atomen,
OCONHR^, wenn R-, Wasserstoff ist, und
tet, wenn R2 Wasserstoff ist, wobei R^ für einen ungesättigten
aliphatischen, cycloaliphatischen oder aromatischen Rest mit 1 bis 6 C-Atomen steht, und in der die 10,11-Doppelbindung
hydriert sein kann.= OCONHR 5 means in which R 1 is an alkyl radical with 1 to 4 carbon atoms, OCONHR ^, when R- is hydrogen, and
tet when R2 is hydrogen, where R ^ is an unsaturated aliphatic, cycloaliphatic or aromatic radical having 1 to 6 carbon atoms, and in which the 10,11 double bond can be hydrogenated.
Es wurde nämlich.überraschenderweise gefunden, daß durch Austausch der Alkylgruppe gegen aliphatische ungesättigte, cycloaliphatische oder aromatische Reste eine erhebliche Verbesserung der Wirkungsqualität erreicht wird. Das trifft sowohl für die α- wie für die ß-Verbindungen zu.It was found, surprisingly, that through exchange the alkyl group compared to aliphatic unsaturated, cycloaliphatic or aromatic radicals a considerable improvement the quality of effect is achieved. This applies to both the α and the ß compounds.
So wirken beispielsweise schon die Allylcarbaminsaureester der 10,11 -nicht hydrierten, wie auch der 10,11 -hydrierten Verbindung der vorgenannten Formel I sehr viel intensiver ZNS-dämpfend oder sie sind weniger toxisch als die entsprechenden n-Propylcarbaminsäureester, wie aus der nachfolgenden Tabelle 1 hervorgeht .For example, the allylcarbamic acid esters of the 10,11 -non hydrogenated, as well as the 10,11 -hydrogenated compound the aforementioned formula I very much more intensive CNS-dampening or they are less toxic than the corresponding n-propylcarbamic acid esters, as can be seen in Table 1 below.
509 8 25/1060509 8 25/1060
ORiGfNAL INSPECTEDORiGfNAL INSPECTED
— 3 — Tabelle- 3 - table
0-CO-NH-R0-CO-NH-R
OCONHROCONHR
-CH2-CH2-CH3 -CH 2 -CH 2 -CH 3
CH2-CH=CHCH 2 -CH = CH
CH2-CH2-CH3 CH 2 -CH 2 -CH 3
CH0-CH=CH0 CH 0 -CH = CH 0
LD1-Q p.o. MausLD 1 -Q po mouse
D150 i.p. Maus
Ptosis MausD 150 ip mouse
Ptosis mouse
verminderte Motilität Mausdecreased mouse motility
Seitenlage (Narkose) Maus Lateral position (anesthesia) mouse
Haffner Reflex
fehlt MausHaffner reflex
missing mouse
619 mg/kg619 mg / kg
516 mg/kg 100 mg/kg516 mg / kg 100 mg / kg
100 mg/kg 100 mg/kg 200 mg/kg100 mg / kg 100 mg / kg 200 mg / kg
970 mg/kg970 mg / kg
444 mg/kg 50 mg/kg444 mg / kg 50 mg / kg
50 mg/kg50 mg / kg
50 mg/kg50 mg / kg
100 mg/kg100 mg / kg
327 mg/kg327 mg / kg
244 mg/kg
100 mg/kg244 mg / kg
100 mg / kg
50 mg/kg
100 mg/kg
100 mg/kg50 mg / kg
100 mg / kg
100 mg / kg
339 mg/kg339 mg / kg
279 mg/kg 100 mg/kg279 mg / kg 100 mg / kg
25 mg/kg 100 mg/kg 100 mg/kg25 mg / kg 100 mg / kg 100 mg / kg
Das im Beispiel 6 beschriebene 4ß-Phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricycloC4,3,1,0 ' Udecari zeigt als . ß-Verbindung keine narkotische Wirkung, jedoch eine Wirkung auf das Nervensystem, die an der weißen Maus als analgetisch (ED50= 140 mg/kg; LD 1500 mg/kg p.o.), muskelrelaxierend (vergleichbar mit Phenobarbital!) und spasmolytisch (ED =0,1 Papaverin und 0,2 ED100 Atropin) erfaßt werden konnten.The 4β-phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricycloC4,3,1,0 'Udecari described in Example 6 shows as. ß-compound no narcotic effect, but an effect on the nervous system, which in the white mouse as analgesic (ED 50 = 140 mg / kg; LD 1500 mg / kg po), muscle relaxant (comparable to phenobarbital!) and spasmolytic (ED = 0.1 papaverine and 0.2 ED 100 atropine) could be detected.
50982 5/1050982 5/10
Die Herstellung der erfindungsgemäßen Carbamate erfolgt wie in der Stammanmeldung P 23 06 118 beschrieben. Die Veresterung der OH-Gruppe in 4-Stellung kann auf bekannte Weise mit einem Isocyanat der allgemeinen Formel R NCO erfolgen, worin FU dieThe carbamates according to the invention are prepared as in the parent application P 23 06 118 described. The esterification of the OH group in the 4-position can be carried out in a known manner with a Isocyanate of the general formula R NCO take place, where FU the
oben angegebene Bedeutung hat. Es ist auch möglich, die OH-Verbindung mit einem entsprechend substituierten Carbaminsäureester oder -chlorid umzusetzen. Die Herstellung der erfindungsgemäßen Carbamate über Phosgen erfolgt durch Reaktion der 4-Hydroxy-8-alkoxy-2,9-dioxatricyclo£4, 3,1,0 ' J decane mit Phosgen zum Chlorameisensäureester, aus dem durch Umsetzung mit dem entsprechenden Amin R1-NH0 das gewünschte Carbamat erhalten wird.has the meaning given above. It is also possible to react the OH compound with an appropriately substituted carbamic acid ester or chloride. The carbamates according to the invention are prepared via phosgene by reacting the 4-hydroxy-8-alkoxy-2,9-dioxatricyclo £ 4, 3,1,0 'I decane with phosgene to give the chloroformic acid ester, from which by reaction with the corresponding amine R 1 -NH 0 the desired carbamate is obtained.
509825/ 1.060509825 / 1.060
4a-N"-Allylcarbaminoyl-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,0 ' Idecan4a-N "-Allylcarbaminoyl-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 'Idecan
5 g 4α-Hydroxy-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1 ,Cr* ' ]decan und 6,5 g Allylisocyanat in 70 ml trockenem Benzol gelöst,wurden 24 Stunden am Rückfluß erhitzt. Dann wurde das Reaktionsgemisch zunächst ■ im Vakuum eingedampft, der Rückstand zur Entfernung von überschüssigem Allylisocyanat mit 50 ml Äthanol versetzt und erneut im Vakuum eingeengt. Danach wurde mit 150 ml · Wasser aufgenommen und 4 χ mit 100 ml Äther extrahiert. Die vereinigten Ätherphasen wurden über Magnesiumsulfat getrocknet, mit etwas Kohle geklärt und nach Filtration im Vakuum eingedampft. Es resultierten 7,5 g kristallines Rohprodukt, Nach Umkristallisieren' aus Äther/Hexan (1:9; V/V) wurden 4,5 g weiße Kristalle erhalten (71,5 % der Theorie). .5 g of 4α-hydroxy-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1, Cr * '] decane and 6.5 g of allyl isocyanate dissolved in 70 ml of dry benzene were 24 Heated at reflux for hours. The reaction mixture was then first evaporated in vacuo, the residue was treated with 50 ml of ethanol to remove excess allyl isocyanate and again concentrated in vacuo. It was then taken up with 150 ml · water and extracted 4 with 100 ml ether. The combined ether phases were dried over magnesium sulfate, clarified with a little charcoal and, after filtration, evaporated in vacuo. 7.5 g of crystalline crude product resulted. After recrystallization from ether / hexane (1: 9; V / V), 4.5 g of white crystals were obtained (71.5 % of theory). .
15215, M = 295,35 15215 , M = 295.35
Fp. 98-1010C (Kofier, unkorrigiert) [α] ψ + 38 ° (Methanol)Mp. 98-101 0 C (Kofier, uncorrected) [α] ψ + 38 ° (methanol)
509825/1060509825/1060
4ß-N-Allylcart)aminoyl-3-niethyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,0^''Jdecan 4β-N-Allylcart) aminoyl-3-diethyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 ^ "decane
5 g 4ß-Hydroxy-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,0
''Jdecan wurden zunächst analog Beispiel 1 mit Allylisocyanat in Benzol umgesetzt und bearbeitet. Es
wurden erhalten: 7,5 g öliges Rohprodukt. Dieses konnte erst nach Chromatographie an 100 g Kieselgel mit CCl^/CHCl^
(80:20; V:V) so rein erhalten werden, daß es kristallisierte. Ausbeute: 5,0 g weiße Kristalle (79,3 % der Theorie).
C15H21NO5, M = 295,35
Fp. 52-530C (Kofier, unkorrigiert)
[cc] Jp + 46 ° (Methanol)5 g of 4β-hydroxy-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 "decane were first reacted and processed with allyl isocyanate in benzene as in Example 1. The following were obtained: 7.5 g of an oily crude product. This could only be obtained so pure after chromatography on 100 g of silica gel with CCl ^ / CHCl ^ (80:20; V: V) that it crystallized. Yield: 5.0 g of white crystals (79.3 % of theory). C 15 H 21 NO 5 , M = 295.35
Mp. 52-53 0 C (Kofier, uncorrected) [cc] Jp + 46 ° (methanol)
4oc-N-Allylcarbaminoyl-3,10~dimethyl-8-methoxy-2,9-dioxatricyclo[4,3,1,O3 ' 7Jdecan 4oc-N-Allylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1, O 3 ' 7 i-decane
4,53 4a-Hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatrieyclo-[4,3,1jO ' Jdecan wurden mit 4 g Allylisocyanat in Benzol unter Zugabe weniger Tropfen Eisessig 24 Stunden bei 50 600C erhitzt und danach analog Beispiel 1 aufgearbeitet.4.53 4-hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatrieyclo- [4,3,1jO 'Jdecan were mixed with 4 g of allyl isocyanate in benzene with addition of a few drops of glacial acetic acid for 24 hours at 50 60 0 C. heated and then worked up analogously to Example 1.
Nach Umkristallisation des Rohproduktes (6,0 g) aus n-Hexan/ Diäthyläther (1:9; V:V) wurden 4,2 g weißes Kristallisat erhalten (67 % der Theorie).After recrystallization of the crude product (6.0 g) from n-hexane / diethyl ether (1: 9; V: V) 4.2 g of white crystals were obtained (67 % of theory).
C15H23NO5 , M = 297,35C 15 H 23 NO 5 , M = 297.35
Fp 56 - 58 ° C (Kofier, unkorrigiert)Mp 56 - 58 ° C (Kofier, uncorrected)
509825/1060509825/1060
4cx-N-Cyclohexylcarbaminoyl-3,1O-dimethyl-8-methoxy-2,9-dioxatricyclo[4,3,1>0^''Jdecan 4cx -N-Cyclohexylcarbaminoyl-3,1O-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1> 0 ^ "decane
5 g 4a-Hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1,0 ''Jdecan wurden mit 5 g Cyclohexyl!socyanat in 70 ml Benzol unter -Zugabe von 3 Tropfen Eisessig 6 Stunden unter Rückfluß gekocht» Es wurde analog Beispiel 1 aufgearbeitet. Das zunächst ölig angefallene Rohprodukt konnte aus η-Hexan kristallisiert werden. Ausbeute: 6,2 g (das sind 78 % der Theorie).5 g of 4-hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1, 0 '' Jdecan were mixed with 5 g of cyclohexyl! Diisocyanate in 70 ml of benzene under addition was of 3 drops of glacial acetic acid Boiled under reflux for 6 hours. Work-up was carried out as in Example 1. The initially oily crude product could be crystallized from η-hexane. Yield: 6.2 g (that is 78 % of theory).
Weiße Kristalle, C18H29NO5, M = 339,43 · .White crystals, C 18 H 29 NO 5 , M = 339.43 ·.
Fp. 109-1100C (Kofier, unkorrigiert) [a] Q1 - 26 ° (Methanol)-Mp. 109-110 0 C (Kofier, uncorrected) [a] Q 1 - 26 ° (methanol) -
4α-Cyclohexylcarbaminoyl-3-methyl-10-methylen-8-methoxy-2,9-dioxatricyclo[4,3,1,05j7]decan ·4α-Cyclohexylcarbaminoyl-3-methyl-10-methylene-8-methoxy-2,9-dioxatricyclo [4,3,1,0 5j7 ] decane ·
6,5 g ^a-Hydroxy-J-methyl-IO-methylen-e-methoxy-E^-dioxatricyclo
[4,3,1,0 ''Jdecan wurden in Benzol mit 15 g Cyclohexylisocyanat
analog Beispiel 4 umgesetzt und aufgearbei- ■ tet. Da das Endprodukt jedoch nicht kristallisiert werden ·
konnte, wurde eine Reinigung durch Chromatographie an Kieselgel auf Dickschichtplatten vorgenommen, (17 Platten 20 χ 20;
Fließmittel: η-Hexan, Essigsäufeäthylester, n-Propanol
70 : 24 : 6; V : V : V)
Ausbeute: 5,5 g farbloses öl, das sind 59 % der Theorie.6.5 g of a-hydroxy-J-methyl-IO-methylen-e-methoxy-E ^ -dioxatricyclo [4,3,1,0 "decane were reacted in benzene with 15 g of cyclohexyl isocyanate as in Example 4 and worked up ■ tet. However, since the end product could not be crystallized, it was purified by chromatography on silica gel on thick-layer plates (17 plates 20 χ 20; mobile phase: η-hexane, ethyl acetate, n-propanol 70: 24: 6; V: V: V )
Yield: 5.5 g of a colorless oil, that is 59 % of theory.
C18H27NO5 , M = 337,40C 18 H 27 NO 5 , M = 337.40
[ctj ^1 + 62 ° (Methanol) .[ctj ^ 1 + 62 ° (methanol).
609825/10 60609825/10 60
4ß-N-Phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1,03' 7].decan4SS-N-Phenylcarbaminoyl-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1,0 3 '7] .decan
3,4 g 4ß-Hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo[4,3,1»0 ' Jdecan und 5»13 g Phenylisocyanat wurden in 200 ml Benzol, das mit 10 Tropfen Eisessig versetzt war, gelöst und 15 Minuten auf 160C erhitzt. Danach wurde auf Raumtemperatur abgekühlt und 24 Stunden stehengelassen. Anschließend wurde im.Vakuum eingeengt und analog Beispiel 1 aufgearbeitet.3.4 g of 4ß-hydroxy-3,10-dimethyl-8-methoxy-2,9-dioxatricyclo [4,3,1 »0 'i-decane and 5» 13 g of phenyl isocyanate were dissolved in 200 ml of benzene with 10 drops of glacial acetic acid was added, dissolved and heated to 16 0 C for 15 minutes. It was then cooled to room temperature and left to stand for 24 hours. The mixture was then concentrated in a vacuum and worked up analogously to Example 1.
Nach Umkristallisation aus Benzol wurden 4,1 g weißes Kristallisat erhalten, das sind 79 % der Theorie.After recrystallization from benzene, 4.1 g of white crystals were obtained, that is 79 % of theory.
C18H23NO5 ,M= 333,3C 18 H 23 NO 5 , M = 333.3
Fp. 154 -156 ° C (Kofier, unkorrigiert) . · ja] ^0 + 17° (Methanol)Mp 154-156 ° C (Kofier, uncorrected). Yes] ^ 0 + 17 ° (methanol)
509825/106 0509825/106 0
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2306118A DE2306118C3 (en) | 1973-02-08 | 1973-02-08 | S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production |
| DE2362396A DE2362396C2 (en) | 1973-02-08 | 1973-12-15 | 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2306118A DE2306118C3 (en) | 1973-02-08 | 1973-02-08 | S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production |
| DE2362396A DE2362396C2 (en) | 1973-02-08 | 1973-12-15 | 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2362396A1 true DE2362396A1 (en) | 1975-06-19 |
| DE2362396C2 DE2362396C2 (en) | 1982-08-05 |
Family
ID=32963212
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2306118A Expired DE2306118C3 (en) | 1973-02-08 | 1973-02-08 | S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production |
| DE2362396A Expired DE2362396C2 (en) | 1973-02-08 | 1973-12-15 | 3-methyl-10-methylene-2,9-dioxatricyclo [4,3,1,0 → 3 →, → 7 →] decane |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2306118A Expired DE2306118C3 (en) | 1973-02-08 | 1973-02-08 | S-methyl-10-methylene ^ -dioxatricyclo [43,1,037I decane and 3,10-dimethyl2,9-dioxatricyclo [43,1,03 · 7! decane and processes for their production |
Country Status (1)
| Country | Link |
|---|---|
| DE (2) | DE2306118C3 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2730988A1 (en) | 1977-07-08 | 1979-01-25 | Kali Chemie Pharma Gmbh | 3-Azido-methyl-2,9-di:oxa-tri:cyclo-decane derivs. - useful as analgesic, antipyretic and antiphlogistic agents |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2607106C2 (en) | 1976-02-21 | 1986-01-16 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 2,9-Dioxatricyclo [4,3,1,0 → 3 → →, → → 7 →] decane and process for their preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1961433A1 (en) * | 1969-12-08 | 1971-06-16 | Kali Chemie Ag | 3,10-Dioxatricyclo- (2,2,2,22,6?) - decane and process for their preparation |
-
1973
- 1973-02-08 DE DE2306118A patent/DE2306118C3/en not_active Expired
- 1973-12-15 DE DE2362396A patent/DE2362396C2/en not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1961433A1 (en) * | 1969-12-08 | 1971-06-16 | Kali Chemie Ag | 3,10-Dioxatricyclo- (2,2,2,22,6?) - decane and process for their preparation |
Non-Patent Citations (1)
| Title |
|---|
| GB-Z: Tetrahedron Letters, Nr. 35, 1970, 3087-90 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2730988A1 (en) | 1977-07-08 | 1979-01-25 | Kali Chemie Pharma Gmbh | 3-Azido-methyl-2,9-di:oxa-tri:cyclo-decane derivs. - useful as analgesic, antipyretic and antiphlogistic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2306118B2 (en) | 1980-02-07 |
| DE2362396C2 (en) | 1982-08-05 |
| DE2306118A1 (en) | 1974-08-15 |
| DE2306118C3 (en) | 1980-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1159462B (en) | Process for the preparation of s-triazine derivatives | |
| DE2362396A1 (en) | CARBAMATES OF 4-HYDROXY-8-ALKOXY-2,9DIOXATRICYCLO SQUARE BRACKET TO 4,3,1,0 HIGH 3,7 SQUARE BRACKET TO DECANES | |
| DE1668425A1 (en) | Process for the preparation of diorganoantimony acylates | |
| DE2205144A1 (en) | Thiazoline and thiazolidinazetidinones | |
| DE1227914B (en) | Process for the preparation of 3- (1, 2-dithia-cyclopentyl) -5-pentanoic acid | |
| EP0087585A1 (en) | Method for the preparation of 3-alkoxy-acrylonitriles | |
| WO2007009143A2 (en) | Method for producing nebivolol | |
| CH497408A (en) | Testosterone derivs having androgenic-anabolic activity | |
| DE2331044A1 (en) | DIPHENYLMETHANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | |
| DE1158500B (en) | Process for the production of polyisonitriles | |
| DE2613306C2 (en) | ||
| DE2351556C2 (en) | Process for the preparation of N-haloformyl-carbamic acid halides | |
| DE2065698A1 (en) | PROCESS FOR THE PREPARATION OF 2ISOPROPYL-6-METHYL-4 (3H) -PYRIMIDONE | |
| EP0560158A2 (en) | Process for the preparation of beta-aminoacrylic acid esters | |
| DE2509780A1 (en) | TRIS- (2-HYDROXYARYL) -CYANURIC ACID ESTER | |
| DE2245611A1 (en) | PROCESS FOR MANUFACTURING ORGANIC ISOCYANATES | |
| DE3150918C1 (en) | Process for the preparation of anilides in the ergoline series | |
| DE3508563C1 (en) | Process for the preparation of 2-isocyanato-2,3-dehydrocarboxylic acid esters | |
| DE1953059C (en) | Carbamic acid derivatives | |
| DE1247294B (en) | Process for the preparation of 2-chloro-3-oxobutyric acid amides | |
| DE1695757C3 (en) | Pyridine methanol carbamates and processes for their preparation | |
| DE1770183A1 (en) | New tertiary ester salts and processes for making the same | |
| DE1057133B (en) | Process for the production of new, pharmacologically active 1,1-diphenyl-2-aminoalkanols | |
| DE951630C (en) | Process for the preparation of 22-tertiary-aminobisnorcholanes unsaturated in the 20 (22) position | |
| DE1953059A1 (en) | Carbamic acid derivatives and processes for making the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8126 | Change of the secondary classification |
Ipc: ENTFAELLT |
|
| AF | Is addition to no. |
Ref country code: DE Ref document number: 2306118 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| 8340 | Patent of addition ceased/non-payment of fee of main patent |